DelveInsight’s, “Advanced Gastric Carcinoma Pipeline Insight, 2023,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Advanced Gastric Carcinoma pipeline landscape. It covers the Advanced Gastric Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Gastric Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Advanced Gastric Carcinoma Pipeline Report

• DelveInsight’s Advanced Gastric Carcinoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Advanced Gastric Carcinoma treatment.
• The leading companies working in the Advanced Gastric Carcinoma Market include Jiangsu Hengrui Medicine, BeiGene, CSPC ZhongQi Pharmaceutical Technology, LintonPharm Co.,Ltd., Bristol-Myers quibb, Hanmi Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Idience Co., Ltd.,  Shanghai Henlius Biotech, AstraZeneca, Nanjing Legend Biotech Co., ALX Oncology Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Genentech, Innovent Biologics (Suzhou) Co. Ltd., Qilu Pharmaceutical Co., Ltd., NextCure, Inc., Chengdu Kanghong Biotech Co., Ltd., GeneQuantum Healthcare (Suzhou) Co., Ltd., Janssen Pharmaceutical K.K., Shanghai Miracogen Inc., Ambrx, Inc., Imugene Limited, Vedanta Biosciences, Inc., Celon Pharma SA, Bicycle Tx Limited, Seagen Inc., and others.
• Promising Advanced Gastric Carcinoma Pipeline Therapies in the various stages of development include pemetrexed, oxaliplatin, Catumaxomab, and others.
• November 2023: Hoffmann- La Roche announced a study of Phase 2 clinical trials for Atezolizumab and Trastuzumab. This is a phase II, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of perioperative trastuzumab+XELOX with / without atezolizumab in participants eligible for surgery with locally advanced HER2-positive gastric cancer or adenocarcinoma of GEJ.
• October 2023: Qun Zhao announced a study of Phase 2 clinical trials for docetaxel, 0xaliplatin, capecitabine. The purpose of this study is to assess the relationship of pCR rate and efficacy by comparing the two drugs and three drugs as neoadjuvant chemotherapy in advanced gastric cancer patients.
• October 2023: Minneamrita Therapeutics LLC announced a study of Phase 1 clinical trials for Minnelide. A Phase 1, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™ Capsules given alone or in combination with paclitaxel in patients with Advanced Gastric Cancer. Minnelide™ is a water soluble disodium salt variant of triptolide, a diterpenoid, an HSP70 inhibitor. Studies using orthotopic pancreatic cancer cell lines and human xenograft transplants demonstrate that Minnelide™ prevents tumor progression, increases survival, and causes tumor regression.

 

Request a sample and discover the recent advances in Advanced Gastric Carcinoma Treatment Drugs @ Advanced Gastric Carcinoma Pipeline Report

 

In the Advanced Gastric Carcinoma pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Gastric Carcinoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Advanced Gastric Carcinoma Overview

Advanced stomach cancer means that a cancer that began in the stomach has spread to at least one other part of the body, such as the liver or lungs. Stomach cancer can spread to the: liver, lungs, lymph nodes, and tissue lining the abdominal cavity (peritoneum). The symptoms of advanced stomach cancer depend on what part of the body the cancer has spread to.

 

Find out more about Advanced Gastric Carcinoma Therapeutics Assessment @ Advanced Gastric Carcinoma Preclinical and Discovery Stage Products

 

Advanced Gastric Carcinoma Emerging Drugs Profile

• Camrelizumab: Jiangsu Hengrui Medicine
• Pamiparib: BeiGene

 

Advanced Gastric Carcinoma Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the Advanced Gastric Carcinoma therapies. The Advanced Gastric Carcinoma companies which have their Advanced Gastric Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Jiangsu Hengrui Medicine.

 

DelveInsight’s Advanced Gastric Carcinoma Pipeline Report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Advanced Gastric Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

 

Advanced Gastric Carcinoma Pipeline Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

 

Learn more about the emerging Advanced Gastric Carcinoma Pipeline Therapies @ Advanced Gastric Carcinoma Clinical Trials Assessment

 

Scope of the Advanced Gastric Carcinoma Pipeline Report

• Coverage- Global
• Advanced Gastric Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Advanced Gastric Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Advanced Gastric Carcinoma Companies- Jiangsu Hengrui Medicine, BeiGene, CSPC ZhongQi Pharmaceutical Technology, LintonPharm Co.,Ltd., Bristol-Myers quibb, Hanmi Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Idience Co., Ltd.,  Shanghai Henlius Biotech, AstraZeneca, Nanjing Legend Biotech Co., ALX Oncology Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Genentech, Innovent Biologics (Suzhou) Co. Ltd., Qilu Pharmaceutical Co., Ltd., NextCure, Inc., Chengdu Kanghong Biotech Co., Ltd., GeneQuantum Healthcare (Suzhou) Co., Ltd., Janssen Pharmaceutical K.K., Shanghai Miracogen Inc., Ambrx, Inc., Imugene Limited, Vedanta Biosciences, Inc., Celon Pharma SA, Bicycle Tx Limited, Seagen Inc., and others.
• Advanced Gastric Carcinoma Pipeline Therapies- pemetrexed, oxaliplatin, Catumaxomab, and others.

 

Dive deep into rich insights for new drugs for Advanced Gastric Carcinoma Treatment, Visit @ Advanced Gastric Carcinoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Advanced Gastric Carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Advanced Gastric Carcinoma – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Camrelizumab: Jiangsu Hengrui Medicine
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Pamiparib: BeiGene
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Venadaparib: Idience
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Advanced Gastric Carcinoma Key Companies
21. Advanced Gastric Carcinoma Key Products
22. Advanced Gastric Carcinoma- Unmet Needs
23. Advanced Gastric Carcinoma- Market Drivers and Barriers
24. Advanced Gastric Carcinoma- Future Perspectives and Conclusion
25. Advanced Gastric Carcinoma Analyst Views
26. Advanced Gastric Carcinoma Key Companies
27. Appendix

 

For further information on the Advanced Gastric Carcinoma Pipeline therapeutics, reach out to Advanced Gastric Carcinoma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment